Nyxoah SA (NYXH) Stock Analysis and Metrics

Nyxoah

NASDAQ: NYXH

$1.40 ▼ -0.07 (-4.76%)

At close: Jul 24, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap53.92 Mn

P/E0.00

P/S3.02

Div. Yield0.00

ROIC (Qtr)-4.45

Revenue Growth (1y) (Qtr)566.54

Add ratio to table…

About

Nyxoah SA is a medical technology company focused on developing and commercializing innovative solutions for the treatment of Obstructive Sleep Apnea, or OSA. Its lead product is the Genio system, a CE-Marked and FDA-approved hypoglossal neurostimulation therapy designed for moderate to severe OSA patients who have failed or cannot tolerate conventional positive airway pressure treatments. The system features a leadless, externally powered neurostimulator implanted via a single-incision procedure to deliver bilateral stimulation of the hypoglossal nerve, maintaining upper airway patency during sleep.

Nyxoah SA generates revenue primarily through the sale of the Genio system, which includes the implantable stimulator, external activation chip, disposable patch, charging unit, and related accessories. The company sells its products to hospitals, sleep centers, and healthcare providers where ear, nose, and throat specialists, sleep physicians, and general practitioners diagnose and treat OSA patients. Revenue began in Europe in July 2020 following CE Mark approval and expanded to the United States in September 2025 after receiving FDA approval for a subset of adult patients with moderate to severe OSA.

The company operates through the following segments:

• Genio system: This segment encompasses the development, manufacturing, and commercialization of the Genio hypoglossal neurostimulation system for the treatment of moderate to severe Obstructive Sleep Apnea. The system includes the Genio implantable stimulator, the external activation chip, the disposable patch, the charging unit, the external stimulator, the sleep lab application, and the smartphone application. The Genio 2.1 system, an updated version featuring Bluetooth capability and enhanced patient feedback through a smartphone application, is also part of this segment.

Nyxoah SA holds a differentiated position in the OSA treatment market due to its leadless, externally powered design and bilateral stimulation capability, which distinguishes it from competing hypoglossal nerve stimulation devices that typically require implantable batteries and multiple leads. The Genio system is the only neurostimulation therapy with MR Conditional labeling for full-body MRI scans at both 1.5T and 3T under both CE Mark and FDA approvals, providing a significant advantage over competitors whose devices are either MR Unsafe or only conditionally safe at 1.5T. The company’s technology addresses a substantial unmet need, as an estimated 35% of moderate to severe OSA patients in the United States suffer from complete concentric collapse, a condition that contraindicates other available HGNS therapies but is treatable with the Genio system.

Nyxoah SA serves hospitals, sleep centers, and healthcare providers where physicians specializing in otolaryngology, sleep medicine, and general practice diagnose and treat patients with moderate to severe Obstructive Sleep Apnea. The company targets high-volume ENT and sleep centers to establish long-term partnerships and develop Centers of Excellence for the Genio system. Specific customer accounts include activated accounts in the United States where surgeons have been trained and the system has been approved through value analysis committee processes, as well as implant centers in Germany, Switzerland, Spain, Finland, Austria, England, the United Arab Emirates, and the Netherlands.

Investment Thesis

▲ Bull case

Nyxoah S.A. is positioned to capture significant market share in the U.S. hypoglossal nerve stimulation (HGNS) market through its differentiated Genio system, which offers bilateral stimulation, single-incision implantation, and full-body MRI compatibility—key advantages that directly address surgeon and patient preferences for minimally invasive, flexible therapy options. The company has already trained 145 surgeons across 120 high-volume accounts and secured value analysis committee (VAC) approval in 57 of these accounts by Q4 2025, demonstrating rapid clinical adoption despite being in the early stages of commercialization. With the expansion of its sales force to 40 reps targeting 200 of the top 400 HGNS accounts in 2026, Nyxoah is systematically building infrastructure to scale beyond initial launch momentum. The company’s reimbursement strategy has proven resilient, with CMS establishing interim C-codes that align Genio’s facility fee at $31,526—equivalent to competitors—eliminating a potential barrier to hospital adoption. Furthermore, commercial payers, representing ~90% of revenue, continue to process claims under established CPT codes with strong prior authorization outcomes, indicating that reimbursement maturation is proceeding normally without adverse impact on uptake. The upcoming 12-month data from the ACCESS study on complete concentric collapse, expected by June 2026, could support a PMA supplement submission for label expansion in early 2027, potentially broadening the addressable patient population and reinforcing Genio’s clinical differentiation in a market where competitors rely on unilateral, pacemaker-based systems. This clinical advancement, combined with plans to launch a next-generation disposable patch (Genio 2.2) in 2027 that could reduce costs and improve gross margins into the 70% range, creates a clear pathway to improved profitability as revenue scales. Nyxoah’s cash position of €48,000,000 as of year-end 2025, coupled with a guided cash burn of ~€20,000,000 per quarter, provides sufficient runway into 2027 even before meaningful revenue contribution from U.S. sales scales, reducing near-term financing risk and allowing management to focus on execution rather than capital constraints.

Nyxoah S.A. is positioned to capture significant market share in the U.S. hypoglossal nerve stimulation (HGNS) market through its differentiated Genio system, which offers bilateral stimulation, single-incision implantation, and full-body MRI compatibility—key advantages that directly address surgeon and patient preferences for minimally invasive, flexible therapy options. The company has already trained 145 surgeons across 120 high-volume accounts and secured value analysis committee (VAC) approval in 57 of these accounts by Q4 2025, demonstrating rapid clinical adoption despite being in the early stages of commercialization. With the expansion of its sales force to 40 reps targeting 200 of the top 400 HGNS accounts in 2026, Nyxoah is systematically building infrastructure to scale beyond initial launch momentum. The company’s reimbursement strategy has proven resilient, with CMS establishing interim C-codes that align Genio’s facility fee at $31,526—equivalent to competitors—eliminating a potential barrier to hospital adoption. Furthermore, commercial payers, representing ~90% of revenue, continue to process claims under established CPT codes with strong prior authorization outcomes, indicating that reimbursement maturation is proceeding normally without adverse impact on uptake. The upcoming 12-month data from the ACCESS study on complete concentric collapse, expected by June 2026, could support a PMA supplement submission for label expansion in early 2027, potentially broadening the addressable patient population and reinforcing Genio’s clinical differentiation in a market where competitors rely on unilateral, pacemaker-based systems. This clinical advancement, combined with plans to launch a next-generation disposable patch (Genio 2.2) in 2027 that could reduce costs and improve gross margins into the 70% range, creates a clear pathway to improved profitability as revenue scales. Nyxoah’s cash position of €48,000,000 as of year-end 2025, coupled with a guided cash burn of ~€20,000,000 per quarter, provides sufficient runway into 2027 even before meaningful revenue contribution from U.S. sales scales, reducing near-term financing risk and allowing management to focus on execution rather than capital constraints.

▼ Bear case

Nyxoah S.A. faces significant near-term execution risks in its U.S. commercialization effort that the market may be underestimating, particularly surrounding the slow and unpredictable pace of value analysis committee (VAC) approvals, which remain a critical gatekeeper to hospital access despite strong surgeon training and engagement. Although the company reported 57 VAC approvals out of 120 submissions by end-Q4 2025, the approval process varies widely by institution—sometimes taking weeks, sometimes months—and there is no guarantee that the remaining 63 submissions will convert at a similar or faster rate, especially as Nyxoah expands into additional accounts beyond its initial 125-target focus. The reliance on a direct sales model requiring surgeon-led patient identification and case-by-case implant planning introduces variability in revenue recognition, as evidenced by the company’s deliberate avoidance of disclosing implant numbers and its emphasis on providing only “backup” devices (one to two extra units) per case, suggesting that a portion of reported revenue may reflect units held by hospitals or surgeons rather than implanted devices, creating potential revenue deferral and inventory buildup risks not fully captured in guidance. Furthermore, while Nyxoah emphasizes its differentiated bilateral stimulation and single-incision design, competitors like LivaNova are preparing to enter the market with pacemaker-based systems that may benefit from entrenched referral patterns, established sleep physician relationships, and potential cost advantages at scale, particularly if Nyxoah fails to rapidly convert surgeon interest into consistent procedural volume. The company’s guidance for 25% sequential U.S. net revenue growth in 2026 appears optimistic given that Q4 2025 net revenue was only €3,500,000, implying a full-year 2026 U.S. run rate of just €14,000,000 if growth is linear—a modest base from which to achieve meaningful scale in the world’s largest HGNS market. This slow uptake is compounded by the fact that Nyxoah does not disclose actual implant volumes, making it difficult to validate whether revenue growth reflects true procedural adoption or merely channel inventory filling, a concern heightened by anecdotal reports of competitors maintaining significant on-shelf inventories at new sites. Finally, while the company anticipates gross margin expansion driven by volume and a future Genio 2.2 patch in 2027, its current gross margin of 63% remains dependent on a complex disposable patch activation system, and any delay in next-generation product development or failure to reduce patch costs could keep margins constrained, exacerbating operating losses that totaled €83,500,000 in 2025 despite only €10,000,000 in net revenue—a trajectory that raises serious questions about the timing and sustainability of profitability even under bullish adoption scenarios.

Nyxoah S.A. faces significant near-term execution risks in its U.S. commercialization effort that the market may be underestimating, particularly surrounding the slow and unpredictable pace of value analysis committee (VAC) approvals, which remain a critical gatekeeper to hospital access despite strong surgeon training and engagement. Although the company reported 57 VAC approvals out of 120 submissions by end-Q4 2025, the approval process varies widely by institution—sometimes taking weeks, sometimes months—and there is no guarantee that the remaining 63 submissions will convert at a similar or faster rate, especially as Nyxoah expands into additional accounts beyond its initial 125-target focus. The reliance on a direct sales model requiring surgeon-led patient identification and case-by-case implant planning introduces variability in revenue recognition, as evidenced by the company’s deliberate avoidance of disclosing implant numbers and its emphasis on providing only “backup” devices (one to two extra units) per case, suggesting that a portion of reported revenue may reflect units held by hospitals or surgeons rather than implanted devices, creating potential revenue deferral and inventory buildup risks not fully captured in guidance. Furthermore, while Nyxoah emphasizes its differentiated bilateral stimulation and single-incision design, competitors like LivaNova are preparing to enter the market with pacemaker-based systems that may benefit from entrenched referral patterns, established sleep physician relationships, and potential cost advantages at scale, particularly if Nyxoah fails to rapidly convert surgeon interest into consistent procedural volume. The company’s guidance for 25% sequential U.S. net revenue growth in 2026 appears optimistic given that Q4 2025 net revenue was only €3,500,000, implying a full-year 2026 U.S. run rate of just €14,000,000 if growth is linear—a modest base from which to achieve meaningful scale in the world’s largest HGNS market. This slow uptake is compounded by the fact that Nyxoah does not disclose actual implant volumes, making it difficult to validate whether revenue growth reflects true procedural adoption or merely channel inventory filling, a concern heightened by anecdotal reports of competitors maintaining significant on-shelf inventories at new sites. Finally, while the company anticipates gross margin expansion driven by volume and a future Genio 2.2 patch in 2027, its current gross margin of 63% remains dependent on a complex disposable patch activation system, and any delay in next-generation product development or failure to reduce patch costs could keep margins constrained, exacerbating operating losses that totaled €83,500,000 in 2025 despite only €10,000,000 in net revenue—a trajectory that raises serious questions about the timing and sustainability of profitability even under bullish adoption scenarios.

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password